Acacia Pharma Group Plc
Acacia Pharma Group Plc
  • Products
    • Overview
    • Therapeutic Areas
    • Marketed Products
    • APD403
  • Partnering
  • Media
    • Press Releases
    • Events
  • Investors
    • Overview
    • Regulatory Announcements
    • Shareholding Structure
    • Share Information
    • Share Price and Charts
    • Financial Reports and Presentations
    • Shareholder Meetings
    • Financial Calendar
    • Analysts
    • Corporate Governance
    • California Compliance statement
    • Comprehensive Compliance Plan
    • Warning for Shareholders
    • Subscribe for Updates
    • Offering Documents
  • Contact
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Site map
Acacia Pharma Group Plc
  • Products
    • Overview
    • Therapeutic Areas
    • Marketed Products
    • APD403
  • Partnering
  • Media
    • Press Releases
    • Events
  • Investors
    • Overview
    • Regulatory Announcements
    • Shareholding Structure
    • Share Information
    • Share Price and Charts
    • Financial Reports and Presentations
    • Shareholder Meetings
    • Financial Calendar
    • Analysts
    • Corporate Governance
    • California Compliance statement
    • Comprehensive Compliance Plan
    • Warning for Shareholders
    • Subscribe for Updates
    • Offering Documents
  • Contact

Transforming medicine

Advancing care

Home > News > Archive: 2019

Press Releases

26 September 2019

Acacia Pharma Announces New BARHEMSYS® PDUFA Target Date of 26 February 2020

05 September 2019

Interim Results for the Six Months ended 30 June 2019

18 July 2019

Founder Dr. Julian Gilbert steps down - Michael Bolinder, Chief Commercial Officer, becomes CEO in Planned Succession

12 July 2019

Editorial on Positive Data for BARHEMSYS® Treatment of PONV Published in Anesthesia & Analgesia

08 July 2019

Acacia Pharma Plans to Resubmit the BARHEMSYS® NDA in Q3 2019

03 June 2019

Annual General Meeting Results and Statement

10 May 2019

Acacia Pharma’s BARHEMSYS® Significantly Improves Post-operative Nausea & Vomiting (PONV) in Rescue Treatment of Ambulatory Patients

07 May 2019

Notice of Annual General Meeting

03 May 2019

Acacia Pharma Receives Complete Response Letter from FDA for BARHEMSYS®

25 April 2019

Positive Phase 3 BARHEMSYS® Rescue Treatment Data to be Presented at the Annual Congress of Enhanced Recovery and Perioperative Medicine

27 February 2019

Results for the year ended 31 December 2018

28 January 2019

Editorial in Anesthesiology on Positive Data for BARHEMSYS™ PONV Rescue Treatment

22 January 2019

Supportive Cardiac Safety Data for BARHEMSYS™

  • 2022 (5)
  • 2021 (16)
  • 2020 (18)
  • 2019 (13)
  • 2018 (14)
  • 2017 (1)
  • 2016 (3)
  • 2015 (4)
  • 2014 (1)
  • 2013 (4)
  • 2012 (3)
  • 2011 (7)
  • 2010 (1)
  • 2009 (5)
  • 2008 (3)
Acacia Pharma Group Plc
  • Terms & Conditions
  • Privacy Policy
  • Cookie Policy
  • Site map

© 2023 Acacia Pharma Group Plc

(Registered in England and Wales No: 09759376)
Registered office address: The Officers’ Mess, Royston Road, Duxford, Cambridge CB22 4QH, UK

Acacia Pharma Limited (Registered in England and Wales No: 05934843) and Acacia Pharma Inc (Incorporated under the laws of Delaware, No: 5799660) are members of the Acacia Pharma Group

Website by Instinctif Partners

By continuing to use acaciapharma.com you will be agreeing to the website Terms & Conditions, the Privacy Policy, and the use of Cookies.